Rachel G Miller

Contributions to Public Health

• Epidemiology and pathogenesis of complication development in type 1 diabetes: I have been a collaborator on the Pittsburgh Epidemiology of Diabetes Complications (EDC) study since 2005. I am particularly interested in the heterogeneity of diabetes complication risk and how longitudinal data can be leveraged to optimize identification of risk factors to prevent and delay complications.
  • Miller RG, Orchard TJ, Costacou T. 30-Year Cardiovascular Disease in Type 1 Diabetes: Risk and Risk Factors Differ by Long-Term Patterns of Glycemic Control. Diabetes Care. 2022; 45(1): 142-150.
  • Miller RG, Anderson SJ, Costacou T, Sekikawa A, Orchard TJ. Hemoglobin A1c and cardiovascular disease incidence in type 1 diabetes: An application of joint modeling of longitudinal and time-to-event data in the Pittsburgh Epidemiology of Diabetes Complications Study. American Journal of Epidemiology. 2018; 187(7): 1520-1529.
• Interplay between genetic/epigenetic factors and glycemic control: I am PI of an R01 which aims to identify genetic variants and inflammatory proteins associated with susceptibility to myocardial infection or fatal CAD in type 1 diabetes and how those associations are affected by glycemic control (R01HL161879). I am also past PI of a project examining DNA methylation and complications of type 1 diabetes, funded by the American Diabetes Association.
  • Miller RG, Mychaleckyj JC, Onengut-Gumuscu S, Feingold E, Orchard TJ, Costacou T. DNA methylation and 28-year cardiovascular disease risk in type 1 diabetes: The Epidemiology of Diabetes Complications (EDC) cohort study. Clinical Epigenetics. 2023; 15: 122.
  • Miller RG, Mychaleckyj JC, Onengut-Gumuscu S, Orchard TJ, Costacou T. TXNIP DNA methylation is associated with glycemic control over 28 years in type 1 diabetes: findings from the Pittsburgh Epidemiology of Diabetes Complications (EDC) study. BMJ Open Diabetes Research and Care. 2023;11(1): e003068.
• Women’s health research: I am PI of an American Diabetes Association Innovative Clinical and Translational Science Women’s Health Award to study complication risk factors across different life stages in women living with type 1 diabetes (Grant #7-23-ICTSWH-19). The study aims to advance understanding of sex-specific complication risk and inform optimal timing for interventions to reduce complication risk. I am also a coordinating center statistician for the Study of Women’s Health Across the Nation (SWAN).
• Statistical analyses of translational effectiveness trials: I have served as a statistician on several community-based translational/effectiveness trials of lifestyle modifications to prevent type 2 diabetes and cardiovascular disease including Physical Activity and Sedentary Behavior Change Impact on Lifestyle Intervention Effects for Diabetes Translation and Diabetes Prevention Translation Project - The healthy LIFESTYLE Program.